麻豆传媒

Dr. Eric Winer is the Director of Yale Cancer Center and Physician-in-Chief of Smilow Cancer Hospital at Yale New Haven as of February 1, 2022. He is also the Alfred Gilman Professor of Medicine and Pharmacology. An internationally renowned expert in breast cancer, Dr. Winer has led and collaborated on innumerable clinical trials that have changed the face of the disease.

Roswell Park Alliance Foundation Endowed Chair in Cancer Prevention and Senior Vice President of Population Sciences, Roswell Park Cancer Institute

Chair of Diagnostic Imaging, Roswell Park Comprehensive Cancer Center Areas of expertise: Breast cancer early detection, mammography/breast imaging, breast biopsy, breast cancer screening, radiology

Vice President for Healthcare Outcomes and Policy, Roswell Park Cancer Institute Areas of expertise: Breast cancer, breast cancer surgery, cancer incidence, health care delivery, measuring quality of health care, health care outcomes

Neil B. Friedman, M.D., FACS, is Director of The Hoffberger Breast Center at Mercy as well as Medical Director of The Weinberg Center for Women's Health and Medicine at Mercy. As a catalyst for advancing breast cancer treatment, Dr. Friedman has partnered with many prestigious national and local organizations to improve the treatment options for women with breast cancer. Likewise, on a very personal level, he partners with each of his patients and their families to help them face the challenges and triumphs of living with a breast cancer diagnosis. Dr. Friedman led the charge to bring IORT, Intraoperative Radiotherapy, to Mercy making it the first hospital in Maryland to offer this leading-edge technology. Dr. Friedmane began his medical career as Chief Resident at the nationally renowned Memorial Sloan-Kettering Cancer Center in New York. He is a Board Certified breast cancer doctor who is dedicated to the search for a cure for cancer. His team continues to lead breast cancer initiatives and introduce best-in-practice breast care treatment options, including Intraoperative Radiotherapy (IORT), an innovative, single-dose radiation treatment, to patients. Dr. Friedman was named Humanitarian of the Year by the Mildred Mindell Cancer Foundation for his efforts in the fight against breast cancer. He has served as a national spokesperson for breast cancer prevention for major organizations such as Bath & Bodyworks. Dr. Friedman has been the Chairman of the American Cancer Society’s Research Administrative Committee, a member of its Executive and Professional Education Committees, and served on its Board of Directors. He has also been involved with the Susan G. Komen Breast Cancer Foundation. Dr. Friedman leads a team of clinicians devoted to breast cancer education, advocating the latest advancements in diagnosis and treatment of breast cancer at a number of conferences, continuing education forums, and patient seminars. Dr. Neil Friedman remains committed in his career to find optimal treatments for breast cancer. Some of his accomplishments include: • Named a “Top Doc” by Baltimore magazine in the Breast Surgery category • Named Humanitarian of the Year by the Mildred Mindell Cancer Foundation • The Breast Center at Mercy Medical Center first in Maryland to offer IORT Treatment • Research on cancer has been published in American Journal of Public Health(APHA) and the Journal of Immunotherapy

Jennifer Joh, M.D., FACS, is a full-time, dedicated breast surgeon at The Hoffberger Breast Center at Mercy in Downtown Baltimore. Dr. Joh also sees patients at select Mercy Community Physician Sites. Devoted to the care of her breast cancer patients, Dr. Joh offers a specialized focus not provided by most breast centers.

As a Board Certified breast cancer doctor with a caring spirit, Dr. Joh treats breast cancer and benign breast conditions with compassion, keeping a patient鈥檚 personal concerns a top priority. Dr. Joh鈥檚 friendly and energetic personality is appreciated by her patients, who easily recognize that patient care is a true commitment and deep source of fulfillment for her. To her patients, Dr. Joh is approachable and easy to communicate with, making the hurdles of breast disease a little more bearable.

Dr. Joh is committed to providing patients with personalized, innovative treatment plans to treat breast diseases. Dr. Joh works with the renowned plastic surgeons at Mercy to offer a full array of breast cancer treatments and breast reconstruction procedures. This team of breast doctors provides an individualized approach to breast surgery so patients are left with a more natural look and shape.

With medical training from the renowned H. Lee Moffitt Cancer Center and Research Institute in Florida, Dr. Joh has a leading edge knowledge base of breast cancers and comprehensive breast cancer treatment.

A published medical expert, Dr. Joh has received recognition by the Annual Multidisciplinary Symposium on Breast Disease for her research on tumor pathology and by the Annual Peter Cyrus-Rizzo III Scientific Seminar for her research on techniques of sentinel lymph node examinations. 

Bonni Lee Guerin, M.D. is a hematologist/oncologist and director of the Breast Cancer Treatment and Prevention Program at Overlook Medical Center, Summit, NJ where she also serves as chair of the Breast Panel, the Multidisciplinary Breast Tumor Board and director of Oncology Education.  

She is the principal investigator of numerous clinical trials exploring new ways to incorporate the latest advances in the management of breast cancer. She is also actively involved in the delivery of highly-specialized immunotherapy, IL-2, for the treatment of melanoma and kidney cancer.

As a medical oncologist with more than 20 years of experience, Dr. Guerin is dedicated to providing the most up to date, cutting edge treatment while looking at each of her patients as an individual. Her philosophy is one of collaboration, working with all members of the care team to provide the best outcome possible. Dr. Guerin believes that compassion and being a good listener, traits she learned from her mother, help tailor a treatment plan that reflects not only the highest order of medical care, but also one that uniquely reflects each and every patient. Dr. Guerin believes it is just as much about living well as it is living long.

Dr. Guerin earned her M.D. at SUNY Stony Brook in 1988, continued her residency at Vanderbilt University in Nashville and completed her fellowship in oncology/hematology at University of California San Diego Cancer Center.  She is board certified in clinical oncology and internal medicine.

Since 2002, Dr. Guerin has served as chair of the Women鈥檚 Oncology Forum, Network for Oncology Communication and Research (NOCR) 鈥� a national organization.  She is a diplomate of the American Society of Clinical Oncology (ASCO) and is a recipient of the Pfizer Award for Excellence in Biochemical Research and a Member of the Expert Panel Consensus Guidelines for Systemic Therapy of Metastatic Renal Cell Carcinoma.  

She has been named by Castle Connelly as one of NY/Metro Top Doctors for the last 10 years, as well as a Top Doctor for Women's Health. She has recently been honored by Curemonos, a New Jersey non-profit organization dedicated to supporting medically underserved women with breast cancer, was the keynote speaker at the American Cancer Society Relay for Life in Chatham, NJ; and was honored at the Society鈥檚 2019 Diamond Ball, in Woodland Park, NJ. 

Her interests are in breast cancer, hepatobiliary cancer and immunotherapy.  

Dr. Priyanka Sharma is an oncologist in Fairway, Kansas and is affiliated with University of Kansas Hospital. She received her medical degree from Baroda Medical College and has been in practice between 11-20 years.

Her specialties are: oncologists diagnose and treat cancers of all types. They use diagnostic tools like biopsies, endoscopies, X-ray and other imaging, nuclear medicine, and blood tests. Cancer surgeons, or surgical oncologists, remove tumors, while medical oncologists treat cancers with chemotherapy. Radiation oncologists use multiple forms of radiation in an effort to eliminate tumors.

Dr. Lynn Dengel is a board-certified and fellowship-trained surgical oncologist specializing in breast cancer and melanoma. She is an Assistant Professor in the Division of Surgical Oncology at the University of Virginia and practices as a breast and melanoma surgeon at Sentara Martha Jefferson Hospital in Charlottesville, Virginia. Dr. Dengel cares for patients in a robust multidisciplinary fashion, utilizes state of the art technology, incorporates up-to-date research findings and takes time to provide education and counseling to her patients to provide outstanding clinical care. Dr. Dengel is recognized by her peers as an expert in breast disease and melanoma. She serves as a committee member for both the Society of Surgical Oncology and the American Society of Breast Surgeons. She has authored and co-authored several articles in leading peer-reviewed publications, including the Annals of Surgical Oncology, Journal of Clinical Oncology, and Annals of Surgery. Dr. Dengel has received recognition for her outstanding research, including the Conquer Cancer Foundation of ASCO Merit Award, supported by Susan G. Komen for the Cure, and the Harvey Baker Traveling Fellow Award from the Society of Surgical Oncology. Research expertise: Dr. Dengel’s research and expertise include translational studies and clinical trials investigating the immune environment at tumor sites and mechanisms that may bolster innate immune response. She is the Principal Investigator of a clinical trial investigating focused ultrasound ablation combined with immunotherapy in advanced solid tumors. Dr. Dengel also serves as lead investigator in multiple studies investigating patient decision making, specifically aiming to improve the process of shared decision making and decreasing decisional regret for patients considering prophylactic mastectomy. Training and education: Dr. Dengel completed a breast surgery fellowship at Memorial Sloan Kettering Cancer Center in New York after finishing her general surgery residency at the University of Virginia Hospital Medical Center in Charlottesville, VA, where she received the Award of Academic Excellence from the department of surgery. Dr. Dengel received her medical degree from the Georgetown University School of Medicine in Washington D.C. where she graduated cum laude and was elected to the Alpha Omega Alpha medical honor society. Prior to medical school, she received her undergraduate degree from Dartmouth College.

The human body is teeming with internal fauna. There are an estimated 10鈥�100 trillion additional cells in this mass of microbes 鈥� roughly equal to the number of human cells in our bodies 鈥� and they are found everywhere, including the breast. Sharma will focus on one such microbe, Bacteroides fragilis, the presence of which in the breast, gut and mammary tissue is linked to a particularly aggressive form of breast cancer.

Jean Sachs has devoted much of her professional career to educating and supporting all people impacted by breast cancer. A social worker by training and at heart, she values making time to connect one-on-one with women when they are struggling with their breast cancer diagnosis. Jean's compassion is matched by her strong business and fundraising skills. Since taking the reins as Executive Director in 1996 (she was named CEO in 2008), Jean has grown LBBC’s annual budget from $100,000 to $6,000,000; earned a 4-Star Charity Navigator rating for the past 17 years, has trained more than 500 leadership volunteers, diversified the organization’s revenue sources, expanded staff capacity and diversity, and strengthened and expanded LBBC programming and partnerships.

Dr. Teplinsky is a board-certified medical oncologist specializing in breast and gynecologic oncology. She is the head of breast and gynecological medical oncology at Valley-Mount Sinai Comprehensive Cancer Care in Paramus, New Jersey, and a clinical assistant professor of medicine at the Icahn School of Medicine at Mount Sinai in New York.









Her clinical and research interests focus on young women with breast cancer, survivorship, exercise oncology, and the use of social media in oncology. She is passionate about oncology education and advocacy on social media and is the host of the INTERLUDE Podcast, where she shares the stories and experiences of those who have been affected by cancer. The podcast provides support, inspiration, encouragement, hope, and strength to others who are going through similar experiences.
You can also follow Dr. Teplinsky's work and advocacy on  and .

Education and Training
Medical School
1992-1996 Dartmouth Medical School

Internship/Residency Combined Program
1996-1999 Stanford University, CA

Fellowship
2000-2003 Harvard Medical School's Combined Program in Pulmonary and Critical Care Medicine, MA

Academic Appointments
Associate Professor, Harvard Medical School
Board Certification
Critical Care Medicine
Pulmonary Medicine

Molly Guthrie serves as Vice President, Policy and Advocacy, where she advances Susan G. Komen’s key legislative and regulatory objectives at the federal, state, and local levels. In this capacity, she is also responsible for leading Komen’s Center for Public Policy and ensuring its work is aligned with meeting the most pressing needs of the breast cancer community. Komen’s legislative efforts focus on policy campaigns to increase funding for medical research and screening programs and ensuring access to affordable, high-quality breast health and cancer care services. In addition to working on policy campaigns, Molly’s team recruits grassroots volunteers across the country to give a personal voice to Komen’s policy and advocacy priorities. Molly joined Susan G. Komen in 2009. Prior to joining Komen, Molly attended the University of Kansas where she received her Bachelor of General Studies with an emphasis on political science and communication studies. She worked in the Offices of Governor Kathleen Sebelius, Congressman Dennis Moore, and the Kansas Health Policy Authority during college.

Maryam Lustberg, MD, MPH, is Director of the Center for Breast Cancer at Smilow Cancer Hospital and Yale Cancer Center, and Chief of Breast Medical Oncology at Yale Cancer Center. She is also an Associate Professor of Medicine (Medical Oncology). She has been recognized for her patient-focused care with awards that include being rated by Forbes as one of the top breast medical oncologists in the nation and named to the Castle Connolly list of 鈥淩egional Top Doctors,鈥� and 鈥淓xceptional Women in Medicine鈥� for 2020. She is currently participating in the American Society of Clinical Oncology (ASCO) Leadership Development Program.

With an emphasis on improving the long-term outcomes for patients with breast cancer who have developed side effects associated with treatment, Dr. Lustberg will continue her research efforts at Yale. She is also focused on investigating novel blood-based biomarkers to identify recurrence and treatment toxicity earlier. She is an NCI-funded investigator and active in both ALLIANCE and SWOG Cancer Cooperative Groups. Dr. Lustberg collaborates widely with researchers from around the world, thriving in creating innovative multidisciplinary scientific teams. Her mentorship has been recognized by numerous awards including Best Teacher Award by Hematology Oncology Fellows and the Shining Star Award for Medical Student Mentorship.
Nationally, Dr. Lustberg is a member of the ASCO Annual Meeting Education Committee, Patient and Survivor Care Education Committee, and Neuropathy Expert Guideline Panel. She is actively engaged in national patient advocacy organizations with a focus on improving shared decision making and increasing patient engagement in clinical trials. In addition, she serves as the President Elect and on the Board of Directors for the international organization Multinational Association of Supportive Care in Cancer (MASCC). She serves as an Associate Editor for the Journal of Cancer Survivorship. In the last decade, she has published over 140 peer-reviewed publications and book chapters.
Dr. Lustberg received her medical degree from the University of Maryland where she also completed her residency and went on to complete a fellowship in medical oncology and in breast medical oncology at The Ohio State University before joining the faculty in 2010. She earned a Master's in Public Health from The Ohio State University in 2013.
Education & Training
MPH
The Ohio State University, Clinical Investigation (2010)
MD
University of Maryland (2003)
Departments & Organizations
Cancer Prevention and ControlCenter for Breast CancerCOPPER CenterInternal MedicineMedical OncologySubset Medical Oncology FacultyYale Cancer CenterYale Medicine

Mehra Golshan, MD, MBA, is a cancer surgeon and a nationally and internationally recognized leader in breast cancer treatment and research. In addition to caring for patients, he serves as Deputy Chief Medical Officer for Surgical Services and Clinical Director of the Breast Cancer Program for the Yale Cancer Center, Smilow Cancer Hospital, and Smilow Cancer Hospital Care Centers.
Dr. Golshan also serves as the Executive Vice Chair for Operations in the Department of Surgery and Professor of Surgical Oncology at the Yale School of Medicine.
Dr. Golshan is a leader in the research with over 150 peer reviewed publications. He has led numerous Phase I, II and III clinical trials and translational science innovations impacting the treatment options and outcomes for women. He is an innovator in tailoring surgery and therapy for women with early stage breast cancer with funding support from the Breast Cancer Research Foundation and National Institutes of Health. He is the principal investigator of several phase II trials aiming to reduce the need for second surgeries or re-excisions in women with breast cancer, one of which uses innovative image-guided operating room capabilities to capture and remove all residual tumor utilizing MRI and mass spectrometry which is used at Yale鈥檚 hybrid operating room.
Dr. Golshan prides himself on being an educator having trained and mentored over a hundred breast surgical fellows as well as international surgeons. He has lectured and taught surgeons, trainees and students nationally and internationally in the field of oncology and breast cancer treatment.
Dr. Golshan is a Board Member of the National Accreditation Program for Breast Centers (NAPBC), Chair of NAPBC Education Committee, Chair of the American College of Surgeons Committee on Interprofessional Education and Practice, and Chair of the American Society of Breast Surgeons Question of the Week Committee.
Dr. Golshan completed his fellowship in breast surgical oncology at Northwestern Memorial Hospital. He earned his Medical Degree from Case Western Reserve University School of Medicine and an MBA at Massachusetts Institute of Technology, Sloan School of Management in Cambridge Massachusetts.
Prior to joining Yale, he spent 17 years in Boston at Harvard鈥檚 Brigham and Women鈥檚 Hospital, Dana Farber Cancer Institute where he was the inaugural and incumbent Dr. Abdul Mohsen and Sultana Al-Tuwaijri Distinguished Chair in Surgical Oncology. He also served as the Director of the Breast Surgical Oncology Fellowship at the Dana-Farber Cancer Institute/Brigham and Women鈥檚 Hospital/Massachusetts General Hospital and was an Associate Professor of Surgery at Harvard Medical School.
Dr. Golshan鈥檚 approach to breast cancer treatment is through a specialized team approach. For each new patient, Smilow brings together a team of medical oncologists, radiation oncologists, reconstruction surgeons, pathologists, genetics, breast imagers, radiologists, program nurses, and a robust clinical research program. 鈥淚 work closely with so many colleagues dedicated deeply to treating and curing breast cancer who inspire me to be a better physician, scientist, and person every day."

Education & Training
MBA
MIT (2019)
Fellow
Northwestern Memorial Hospital (2003)
Resident
Rush Presbyterian St. Luke's Medical Center (2002)
MD
Case Western Reserve University (1996)

Professor, Department of Medicine, School of Medicine
Member, Developmental Therapeutics Program, Case Comprehensive Cancer Center
Research Information
Research Interests:
Dr. Montero's research interests include the improvement of clinical outcomes in patients with breast cancer through the development of novel targeted therapies. He has been the principal investigator in over 30 clinical trials and has co-authored over 50 peer-reviewed publications. He has a particular interest in immune-based therapies in breast cancer and other solid malignancies, and better understanding the various mechanisms by which tumors evade the immune system. Dr. Montero also has a keen interest in process improvement in oncology to develop more effective and efficient treatment strategies in breast cancer that lead to better clinical outcomes and, ultimately, superior quality of care for patients.

External Appointments
Medical Director, Seidman Cancer Center Clinical Trials Unit University Hospitals
Clinical Director, Breast Cancer Program University Hospitals Seidman Cancer Center

Dr. Leonardis earned a BS in Exercise Science from Salisbury University, an MS in Exercise Science from East Carolina University, and a PhD in Kinesiology from the University of Michigan. After the completion of his doctoral studies, Dr. Leonardis completed a postdoctoral fellowship in rehabilitation engineering at the University of Wisconsin-Milwaukee. Dr. Leonardis’s research program studies the intricate relationship between shoulder structure and function using innovative biomechanical, neuromuscular, and musculoskeletal imaging techniques.  Ultimately, Dr. Leonardis aims to develop novel, evidence-based interventions for the prevention, early detection, and treatment of upper extremity pain and pathologies across the life span, with a particular interest in manual wheelchair users and individuals undergoing treatment for breast cancer.

David Rimm is the Anthony N. Brady Professor of Pathology in the Departments of Pathology and Medicine (Oncology) at the Yale University School of Medicine. He is the Director of Yale Pathology Tissue Services and the Lab for Quantitative Diagnostics in Anatomic Pathology. He completed an MD-PhD at Johns Hopkins University Medical School followed by a Pathology Residency at Yale and a Cytopathology Fellowship at the Medical College of Virginia. His research lab group focuses on quantitative pathology using the AQUA® technology invented in his lab, and other quantitative methods, with projects related to predicting response and resistance to both targeted and immune- therapy in cancer. His lab is involved in the use of new high-plex methods including digital spatial profiling (NanoString) for new biomarker discovery. He is also interested in translation of assays to the clinic and standardization of those assays for CLIA labs. The work is supported by grants from the NIH, BCRF, and sponsored research agreements from biopharma. He also serves on the CAP Immunohistochemistry committee and multiple scientific advisory boards for biotech and pharma. He is an author of over 500 peer-reviewed papers with an H-index of 120 and 8 patents.

Susan Brown serves as the Senior Director of Health Information & Publications where she oversees a team responsible for providing relevant breast cancer and breast health information to patients, caregivers, the public, and others through various channels. She provides direction and oversight in the design, development, implementation, and coordination of breast cancer and breast health messages for educational materials, programs, projects, and training. Susan ensures all breast cancer information and messaging associated with Komen is safe, accurate, current, consistent, based on scientific evidence, reader-friendly, and culturally responsive, collaborating with internal and external stakeholders for diverse audience's needs.  
 
Prior to Komen, Susan worked as a professional registered nurse in oncology, focusing on breast cancer exclusively since 1987. As a breast cancer survivor, Susan brings a unique perspective and dedication to advancing breast health globally.